KKR & Co. (NYSE:KKR) drew an Overweight from Barclays with a slightly higher $124 target as the firm expands strategic bets—launching Allyntra to scale med‑tech precision solutions and boosting capital for deals—while leading a A$400m financing to back Ampol’s refinancing and growth.
Previous Week Recap
- Barclays Keeps Overweight On KKR: Barclays kept Overweight on KKR and raised its price target to $124 from $122, citing a firmer near-term outlook; rating unchanged, target up $2.
- KKR Launches Allyntra Platform: KKR launched Allyntra, a precision solutions platform for med-tech and precision markets, expanding its Precipart investment and committing more capital for growth via acquisitions and innovation.
- KKR Leads A$400M Ampol Financing: KKR led and committed to an A$400 million financing package for Ampol, structured to support Ampol’s refinancing and general corporate purposes.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.